AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

¥110.36 +$13.37 (+13.78%)
SHH · 15 Sep 2026 07:00 UTC
Previous Close
¥110.88
Day Range
¥108.68¥111.47
Year Range
¥75.1¥160
Market Cap
29.21B
AVG Volume
6.55M
Trailing/Forward PE
53.2/79.68
PEG ratio
-1.44
Dividend Yield
-
Next Earnings Date
2026-10-26
Primary Exchange
Shanghai Stock ExchangeCN
Revenue (CNY)
0250M500M750M1B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Revenue (CNY) by quarter
PeriodRevenue (CNY)
26 Q2299.99M
26 Q1905.39M
25 Q4217.04M
25 Q3217.79M
25 Q2208.01M
25 Q1167.64M
24 Q4148.84M
24 Q3143.42M
24 Q2132.45M
24 Q1108.24M
Net Income (CNY)
-200M0200M400M600M800M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Net Income (CNY) by quarter
PeriodNet Income (CNY)
26 Q27.4M
26 Q1632.61M
25 Q4-67.28M
25 Q3-20.61M
25 Q2-44.54M
25 Q1-28.26M
24 Q4-39.93M
24 Q3-31.37M
24 Q2-27.04M
24 Q1-39.5M
Operating Income (CNY)
-200M0200M400M600M800M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Operating Income (CNY) by quarter
PeriodOperating Income (CNY)
26 Q2-19.37M
26 Q1630.03M
25 Q4-69M
25 Q3-20.03M
25 Q2-46.71M
25 Q1-30.02M
24 Q4-42.5M
24 Q3-33.11M
24 Q2-33.81M
24 Q1-45.62M
EBITDA (CNY)
-200M0200M400M600M800M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS EBITDA (CNY) by quarter
PeriodEBITDA (CNY)
26 Q2-8.18M
26 Q1641.07M
25 Q4-74.5M
25 Q3-6.82M
25 Q2-29.78M
25 Q1-12.38M
24 Q4-24.62M
24 Q3-16.18M
24 Q2-16.25M
24 Q1-28.13M
Cash Flows (CNY)
-250M0250M500M750M1B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Cash Flows (CNY) by quarter
PeriodCash Flows (CNY)
26 Q238.99M
26 Q1835.27M
25 Q4-51.76M
25 Q3-52.24M
25 Q2-56.67M
25 Q1-40.06M
24 Q4-58.72M
24 Q3-60.13M
24 Q27.01M
24 Q159.03M
EPS (CNY)
-1012324 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS EPS (CNY) by quarter
PeriodEPS (CNY)
26 Q20.03
26 Q12.39
25 Q4-0.27
25 Q3-0.07
25 Q2-0.17
25 Q1-0.11
24 Q4-0.15
24 Q3-0.12
24 Q2-0.1
24 Q1-0.15
Expenses (CNY)
0200M400M600M800MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Expenses (CNY) by quarter
PeriodExpenses (CNY)
26 Q2171.66M
26 Q1277.32M
25 Q4730.03M
25 Q3288.52M
25 Q2279.85M
25 Q1245.18M
24 Q4242.29M
24 Q3191.47M
24 Q2188.69M
24 Q1188.74M
Cash & Debt (CNY)
01B2B3BCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Cash & Debt (CNY) by quarter
PeriodCash & Debt (CNY)
26 Q22.47B
26 Q12.68B
25 Q42.03B
25 Q32.09B
25 Q22.15B
25 Q12.14B
24 Q42.19B
24 Q32.2B
24 Q22.38B
24 Q12.41B
Debt ratios
-100102024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Debt ratios by quarter
PeriodDebt ratios
26 Q2-2.93
26 Q1-3.11
25 Q47.1
25 Q312.78
25 Q212.49
25 Q117.03
24 Q413.75
24 Q310.28
24 Q27.66
24 Q16.63
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Margins by quarter
PeriodMargins
26 Q284.87%
26 Q197.01%
25 Q490.47%
25 Q393.32%
25 Q288.97%
25 Q188.39%
24 Q492.81%
24 Q393.62%
24 Q291.9%
24 Q193.4%
Return on Capital
-20%0%20%40%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Return on Capital by quarter
PeriodReturn on Capital
26 Q20.43%
26 Q136.93%
25 Q4-6.23%
25 Q3-1.79%
25 Q2-3.79%
25 Q1-2.31%
24 Q4-3.19%
24 Q3-2.41%
24 Q2-1.72%
24 Q1-2.47%
Shares Outstanding
0100M200M300M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Shares Outstanding by quarter
PeriodShares Outstanding
26 Q2264.71M
26 Q1264.71M
25 Q4253.04M
25 Q3280.68M
25 Q2263.1M
25 Q1256.93M
24 Q4266.43M
24 Q3261.52M
24 Q2268.96M
24 Q1263.33M
Book Value Per Share (CNY)
0246824 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Book Value Per Share (CNY) by quarter
PeriodBook Value Per Share (CNY)
26 Q26.5
26 Q16.47
25 Q44.27
25 Q34.09
25 Q24.47
25 Q14.76
24 Q44.7
24 Q34.98
24 Q25.83
24 Q16.08
Total Assets (CNY)
01B2B3B4B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
688266.SS Total Assets (CNY) by quarter
PeriodTotal Assets (CNY)
26 Q23.53B
26 Q13.69B
25 Q42.97B
25 Q33.01B
25 Q23B
25 Q12.92B
24 Q43B
24 Q32.97B
24 Q23.1B
24 Q13.1B
PE Ratio
50607080med 64.51Jul 26Jul 26Aug 26Aug 26Sep 26Sep 26
688266.SS PE Ratio by quarter
PeriodPE Ratio
Sep 2658.68
Sep 2656.45
Sep 2662.44
Aug 2663.59
Aug 2668.12
Aug 2663.72
Aug 2664.41
Jul 2664.62
Jul 2671.95
Jul 2668.86
Jul 2676.74
Jul 2675.68
Free Cash Flow Yield
-1%0%1%2%3%med -0.47%Dec 24Apr 25Jul 25Oct 25Feb 26Jun 26Sep 26
688266.SS Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 262.3%
Sep 262.39%
Sep 262.16%
Aug 262.12%
Aug 261.98%
Aug 262.12%
Aug 262.09%
Jul 262.09%
Jul 261.87%
Jul 261.96%
Jul 261.76%
Jul 261.78%
Jun 26-0.74%
Jun 26-0.88%
Jun 26-0.85%
Jun 26-0.87%
May 26-0.79%
May 26-0.78%
May 26-0.78%
May 26-0.78%
Apr 26-0.76%
Apr 26-0.82%
Apr 26-0.8%
Apr 26-0.81%
Apr 26-0.8%
Mar 26-0.73%
Mar 26-0.86%
Mar 26-0.94%
Mar 26-0.9%
Feb 26-0.9%
Feb 26-0.78%
Feb 26-0.81%
Jan 26-0.84%
Jan 26-0.84%
Jan 26-0.79%
Jan 26-0.75%
Dec 25-0.8%
Dec 25-0.82%
Dec 25-0.81%
Dec 25-0.75%
Dec 25-0.74%
Nov 25-0.74%
Nov 25-0.81%
Nov 25-0.77%
Nov 25-0.86%
Oct 25-0.79%
Oct 25-0.8%
Oct 25-0.81%
Oct 25-0.78%
Sep 25-0.73%
Sep 25-0.56%
Sep 25-0.56%
Sep 25-0.53%
Sep 25-0.49%
Aug 25-0.58%
Aug 25-0.54%
Aug 25-0.52%
Aug 25-0.56%
Aug 25-0.52%
Jul 25-0.51%
Jul 25-0.44%
Jul 25-0.49%
Jul 25-0.51%
Jun 25-0.18%
Jun 25-0.18%
Jun 25-0.17%
Jun 25-0.17%
May 25-0.18%
May 25-0.21%
May 25-0.21%
May 25-0.2%
Apr 25-0.18%
Apr 25-0.2%
Apr 25-0.2%
Apr 25-0.19%
Apr 25-0.18%
Mar 25-0.04%
Mar 25-0.04%
Mar 25-0.04%
Mar 25-0.05%
Feb 25-0.05%
Feb 25-0.05%
Feb 25-0.06%
Feb 25-0.06%
Jan 25-0.06%
Jan 25-0.06%
Jan 25-0.06%
Jan 25-0.07%
Jan 25-0.06%
Dec 24-0.34%
Dec 24-0.34%
Dec 24-0.32%
Dec 24-0.31%
Nov 24-0.31%
Nov 24-0.33%
Nov 24-0.33%
Nov 24-0.33%
Nov 24-0.34%
Oct 24-0.33%
Oct 24-0.31%
Price to Sales
0204060med 40.04Dec 24Apr 25Jul 25Oct 25Feb 26Jun 26Sep 26
688266.SS Price to Sales by quarter
PeriodPrice to Sales
Sep 2618.96
Sep 2618.24
Sep 2620.17
Aug 2620.54
Aug 2622.01
Aug 2620.59
Aug 2620.81
Jul 2620.88
Jul 2623.24
Jul 2622.25
Jul 2624.79
Jul 2624.45
Jun 2633.34
Jun 2628
Jun 2629
Jun 2628.31
May 2631.2
May 2631.87
May 2631.95
May 2631.67
Apr 2632.47
Apr 2630.32
Apr 2630.85
Apr 2630.52
Apr 2631.06
Mar 2638.07
Mar 2632.7
Mar 2629.85
Mar 2631.06
Feb 2631.05
Feb 2635.7
Feb 2634.57
Jan 2633.32
Jan 2633.2
Jan 2635.58
Jan 2637.36
Dec 2535.05
Dec 2539.21
Dec 2539.91
Dec 2543.1
Dec 2543.46
Nov 2543.33
Nov 2539.87
Nov 2541.72
Nov 2537.41
Oct 2540.92
Oct 2540.1
Oct 2539.98
Oct 2541.36
Sep 2544.52
Sep 2546.19
Sep 2545.76
Sep 2548.8
Sep 2552.41
Aug 2544.25
Aug 2547.32
Aug 2549.09
Aug 2546.06
Aug 2549.32
Jul 2550.52
Jul 2557.9
Jul 2552.11
Jul 2550.15
Jun 2553.94
Jun 2556.15
Jun 2558.59
Jun 2557.45
May 2554.37
May 2548.05
May 2546.17
May 2549.74
Apr 2554.05
Apr 2550.38
Apr 2549.99
Apr 2552.83
Apr 2554.49
Mar 2552.56
Mar 2549.53
Mar 2548.78
Mar 2546.37
Feb 2543.94
Feb 2539.78
Feb 2536.34
Feb 2534.74
Jan 2535.23
Jan 2535.37
Jan 2534.27
Jan 2531.71
Jan 2532.97
Dec 2441.36
Dec 2441.11
Dec 2444.64
Dec 2445.03
Nov 2445.95
Nov 2442.3
Nov 2443.08
Nov 2442.44
Nov 2441.57
Oct 2443.33
Oct 2445.59
EV/EBITDA
5055606570med 57.78Jul 26Jul 26Aug 26Aug 26Sep 26Sep 26
688266.SS EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 2652.27
Sep 2650.17
Sep 2655.83
Aug 2656.9
Aug 2661.18
Aug 2657.03
Aug 2657.68
Jul 2657.88
Jul 2664.8
Jul 2661.88
Jul 2669.32
Jul 2668.32
Price/Operating Cashflow
0200400600800med 573.87Oct 24Dec 24Feb 25Apr 25May 25Jul 26Sep 26
688266.SS Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2634.29
Sep 2632.98
Sep 2636.48
Aug 2637.15
Aug 2639.8
Aug 2637.23
Aug 2637.63
Jul 2637.76
Jul 2642.04
Jul 2640.23
Jul 2644.84
Jul 2644.22
Jun 25670.5
Jun 25697.91
Jun 25728.29
Jun 25714.12
May 25675.85
May 25597.3
May 25573.87
May 25618.24
Apr 25671.81
Apr 25626.26
Apr 25621.41
Apr 25656.64
Apr 25677.34
Mar 25342.95
Mar 25323.18
Mar 25318.26
Mar 25302.57
Feb 25286.71
Feb 25259.57
Feb 25237.1
Feb 25226.69
Jan 25229.87
Jan 25230.81
Jan 25223.58
Jan 25206.92
Jan 25215.13
Dec 24680.42
Dec 24676.29
Dec 24734.42
Dec 24740.73
Nov 24755.94
Nov 24695.85
Nov 24708.67
Nov 24698.24
Nov 24683.9
Oct 24712.8
Oct 24749.96
Oct 24695.63
Sep 24745.94
Price to Book
1015202530med 21.92Dec 24Apr 25Jul 25Oct 25Feb 26Jun 26Sep 26
688266.SS Price to Book by quarter
PeriodPrice to Book
Sep 2617.13
Sep 2616.48
Sep 2618.23
Aug 2618.57
Aug 2619.89
Aug 2618.6
Aug 2618.81
Jul 2618.87
Jul 2621.01
Jul 2620.11
Jul 2622.41
Jul 2622.1
Jun 2625.01
Jun 2621.01
Jun 2621.75
Jun 2621.24
May 2623.4
May 2623.9
May 2623.97
May 2623.76
Apr 2624.36
Apr 2622.74
Apr 2623.14
Apr 2622.9
Apr 2623.3
Mar 2624.6
Mar 2621.12
Mar 2619.29
Mar 2620.07
Feb 2620.06
Feb 2623.07
Feb 2622.33
Jan 2621.53
Jan 2621.45
Jan 2622.98
Jan 2624.14
Dec 2522.65
Dec 2522.26
Dec 2522.66
Dec 2524.46
Dec 2524.67
Nov 2524.6
Nov 2522.63
Nov 2523.68
Nov 2521.24
Oct 2523.23
Oct 2522.76
Oct 2522.69
Oct 2523.48
Sep 2525.27
Sep 2522.36
Sep 2522.15
Sep 2523.62
Sep 2525.37
Aug 2521.42
Aug 2522.91
Aug 2523.76
Aug 2522.3
Aug 2523.87
Jul 2524.46
Jul 2528.02
Jul 2525.23
Jul 2524.28
Jun 2522.95
Jun 2523.89
Jun 2524.93
Jun 2524.44
May 2523.13
May 2520.44
May 2519.64
May 2521.16
Apr 2523
Apr 2521.44
Apr 2521.27
Apr 2522.48
Apr 2523.18
Mar 2519.71
Mar 2518.57
Mar 2518.29
Mar 2517.39
Feb 2516.47
Feb 2514.91
Feb 2513.62
Feb 2513.03
Jan 2513.21
Jan 2513.26
Jan 2512.85
Jan 2511.89
Jan 2512.36
Dec 2410.74
Dec 2410.67
Dec 2411.59
Dec 2411.69
Nov 2411.93
Nov 2410.98
Nov 2411.18
Nov 2411.02
Nov 2410.79
Oct 2411.25
Oct 2411.84
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
688266.SS
Stockpicker

Video analysis: 688266.SS

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.